Neurosense Therapeutics is trading at $1.35, down 5.59%, with no clear catalyst identified for the November 3 move. - Shares had rebounded in premarket. - Investors may still be weighing PrimeC’s planned Health Canada filing shift from December 2026 to March 2027. - The company says the timing allows new NfL analysis and additional trial data; Health Canada reportedly has no concerns with the revised timeline, while biotech shares are under pressure.